Dulaglutide: Phase III data

Top-line data from the double-blind, international Phase III AWARD-3 trial in 807 patients with early Type II diabetes showed that once-weekly 1.5 mg subcutaneous dulaglutide met the primary endpoint of non-inferiority to metformin in reducing HbA1c from baseline to week 26. Additionally, the trial was designed to assess superiority of both once-weekly 0.75 and 1.5 mg doses of dulaglutide to metformin if the primary endpoint was met. Both doses of dulaglutide significantly reduced HbA1c from baseline to week 26 vs. metformin. The most common adverse events were gastrointestinal-related. ...